Freedman Financial Associates’s Moderna MRNA Stock Holding History

Freedman Financial Associates’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100	Closed	-$17K	–	266
2022 Q1	$17K	Buy	+100	New	+$16.8K	0.01%	313

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Freedman Financial Associates's MRNA Position: Q2 2022 in Review

Freedman Financial Associates sold out of Moderna (MRNA) in Q2 2022, closing a stake of 100 shares — an estimated $17K sold.

Freedman Financial Associates first reported a position in MRNA in Q1 2022 and held it in 1 quarter. The position peaked at $17K in Q1 2022. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

Freedman Financial Associates reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
Freedman Financial Associates sold 100 Moderna shares in Q2 2022, an estimated $17K.
Freedman Financial Associates first reported a position in Moderna in Q1 2022 and held it in 1 quarter.
Freedman Financial Associates's Moderna position peaked at $17K in Q1 2022.
981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.